TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that the first accelerator-based BNCT (AB-BNCT) clinical research center at Xiamen Humanity Hospital (XHH) has now treated 12 patients in its Investigator Initiated Trial (IIT) aimed at evaluating the safety and efficacy of BNCT in the treatment of advanced refractory malignant tumors. Treated with the NeuPex System from Neuboron with TLS’s electrostatic Neutron Beam System (NBS), these are the first human patients treated with AB-BNCT technology outside of Japan.
TLS and Avita Biomedical Announce Strategic Partnership
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), and AIVITA Biomedical, Inc. (AIVITA), a biotech company specializing in innovative stem cell applications, today announced a partnership to address an unmet need in glioblastoma treatment.
TLS Announces Partnership with HDX for BNCT in South Korea
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with HDX Corporation (HDX) to bring TLS’s targeted radiation therapy to South Korea for the treatment of difficult-to-treat cancers, such as brain, head and neck cancers and melanoma.
TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the publication of a study in the September 22 issue of the Journal of Medical Physics that assessed whether alpha particles generated through the combination of boron target drugs and proton radiation would generate a reaction that would be sufficient to enhance the biological effectiveness of proton therapy in the treatment of prostate cancer.
TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting
The session, “New Era in Biologically-Targeted Radiation Therapy: Clinical Application and Technical Advancement in Boron Neutron Capture Therapy” will feature presentations by Timothy Malouff, M.D., Mayo Clinic, Ester Orlandi, M.D., National Center of Oncological Hadrontherapy (CNAO) and Kendall Morrison, Ph.D., Chief Scientific Officer, TAE Life Sciences. They will discuss the clinical application and technical advancements in BNCT for the treatment of invasive, recurrent and difficult to treat cancers.
TAE Life Sciences Partners with BEC to Incorporate Specialized Robotic Patient Positioning System in its Alphabeam™ System for High-Precision Boron Neutron Capture Therapy
During BNCT, it is essential that the patient is positioned accurately in relation to the radiation beam and that the radiation therapist has the ability to adjust the patient’s position throughout the whole treatment session. BEC will be developing a unique chair setup that will allow for flexible patient treatment in a seated position in addition to the traditional treatment couch configuration. Exclusively designed for TLS’ Alphabeam™ Neutron System, the chair is optimal for treating specific types of head and neck cancers.
TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. This technique holds promise in treating patients with cancer for whom other treatment options have been exhausted or are unavailable.
TAE Life Sciences Identifies Proprietary Drug Candidates to Support Boron Neutron Capture Therapy (BNCT)
“TLS is the only company developing comprehensive, in-house target drugs as well as a neutron technology system called Alphabeam™ to enable the next-generation in biologically targeted radiation therapy. Today’s news brings us closer to our goal of providing new hope to patients with the most difficult to treat cancers,” said Bruce Bauer, PhD, CEO of TAE Life Sciences. “Historically, brain, head and neck, and melanoma cancers have been treated with BNCT and studies have shown improvements in survival compared to other cancer therapies. New boron drugs expand the potential to treat other indications including breast, lung and liver cancers.”
TAE Life Sciences and CNAO (National Center of Oncological Hadrontherapy) Announce a Research and Clinical Collaboration for the Implementation of a New Facility with Boron Neutron Capture Therapy System in Italy
TAE Life Sciences (TLS), a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based boron neutron capture therapy (BNCT) system, today announced that it has entered into an agreement with National Center of Oncological Hadrontherapy (CNAO) to provide its Alphabeam™ Neutron System for the treatment of invasive, recurrent and difficult to treat cancers.